Brokers Set Expectations for BioLineRx Ltd.’s Q1 2024 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX) – Equities researchers at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for BioLineRx in a research note issued on Tuesday, March 26th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($0.29) per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for BioLineRx’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.24) EPS and Q4 2024 earnings at ($0.22) EPS.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, March 26th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $4.80 million during the quarter, compared to analyst estimates of $0.17 million. During the same period in the prior year, the firm posted ($0.09) EPS.

Separately, StockNews.com upgraded BioLineRx to a “sell” rating in a research report on Wednesday.

BioLineRx Stock Performance

BLRX stock opened at $1.11 on Thursday. BioLineRx has a twelve month low of $0.81 and a twelve month high of $2.53. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.86 and a current ratio of 1.96. The business has a fifty day moving average of $1.21 and a 200-day moving average of $1.47.

Institutional Investors Weigh In On BioLineRx

Several large investors have recently modified their holdings of BLRX. NorthRock Partners LLC bought a new stake in shares of BioLineRx in the fourth quarter worth about $27,000. B. Riley Wealth Advisors Inc. increased its holdings in shares of BioLineRx by 88.5% in the third quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 10,000 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in shares of BioLineRx during the third quarter worth about $46,000. Renaissance Technologies LLC boosted its position in shares of BioLineRx by 49.1% during the third quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after buying an additional 22,478 shares during the period. Finally, LPL Financial LLC boosted its position in shares of BioLineRx by 152.7% during the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after buying an additional 71,134 shares during the period. 1.56% of the stock is currently owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.